Annual Report

Overview

The report highlights consolidated 2022 revenue of KRW 190.9 billion, continued open-innovation drug development, and a broad social-responsibility program. It describes progress on the JM-010, SOL-804 and lurasidone pipeline, alongside community support through Smart Volunteers and World Vision Korea. It also reports ISO 14001 and ISO 45001 systems at the Ansan plant.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2022
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services